Will Profusa stock go up?

According to Danelfin AI, Profusa has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (36.77%) is -14.05% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Profusa stock?

The Profusa target price is $0.09 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Profusa stock right now?

Profusa has today a Strong Sell rating (AI Score 1/10), according to Danelfin AI. Its probability of beating the market in 3 months (36.77%) is -14.05% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Profusa stock is a good buy .

Is Profusa undervalued right now?

Based on analysts, the average price target downside for Profusa is 0.00% (1Y). According to Danelfin AI, Profusa has today an AI Score of 1/10 (Strong Sell Rating).

What was the price range of Profusa stock over the past 12 months?

The Profusa stock price range over the past 12 months has been $0.09 - $938.25.

What is going on with Profusa stock in the last 3 months?

The Profusa stock performance in the last quarter has been -83.67%.

Does Profusa offer dividend payments?

No, Profusa does not currently pay dividends.

What is the current market capitalization of Profusa?

Profusa's market cap is $440K, as of 2026-07-03 08:00.

Profusa Inc (PFSA) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

PFSA AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Profusa Inc today receives an AI Score of 1/10, which translates to a Strong Sell rating. The stock has a 37% probability of outperforming the market in the next 3 months, which is 14% lower than the average probability of any stock (51%). The top positive contributor is the Chart Pattern (120d) (impact +0.69%), which boosts the probability. However, the strongest detractors include the Industry (GICS) – Health Care Equipment & Supplies (impact -2.52%), Basic EPS Consolidated in the bottom 10% (impact -1.39%), and the Chart Pattern (504d) (impact -1.22%). Other negative factors include the Fear & Greed Index at 31 (impact -1.19%), the Fundamentals Impact (Long Tail) (impact -1.16%), and Maximum Volatility in the top 10% (impact -0.98%). Notable data points include a Basic EPS of -2.05 (bottom 10%), indicating poor profitability, and Institutional Ownership of only 1.56% (bottom 10%), reflecting low confidence from large investors. The ATR (14d Volatility) is in the bottom 10% (value 0.038), suggesting very low price volatility, which can be a positive for stability but also indicates low trading interest. The Plus Directional Indicator (+DI, 90d) is in the top 10% (value 29.98), signaling strong buying pressure, yet this detracts from the probability. Overall, the stock faces significant headwinds from weak fundamentals, low institutional interest, and negative industry and sentiment signals, resulting in a very low AI Score and a strong sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Sentiment-5.52%
How analysts and the market view the stock
Momentum-2.54%
Direction and strength of recent price movements
Valuation-2.13%
How the stock is priced relative to its fundamentals
Volatility-1.39%
How much the stock price tends to fluctuate
Growth-1.39%
Expected pace of revenue and earnings expansion
Size & Liquidity-1.08%
Company size and trading liquidity

PFSA probability advantage of beating the market (3M):

-14.05%

Technical

Profusa (PFSA) has a Technical Score of 2/10 because, according to only technical analysis, it has a probability advantage of -8.91% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.73%) and the probability of PFSA (41.82%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.73%
PFSA probability advantage of beating the market (only technical, 3M)-8.91%
PFSA probability of beating the market (3M)41.82%

PFSA probability advantage of beating the market (only technical, 3M): -8.91%

The AI-powered technical analysis of Profusa (PFSA) is only based on the 29 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of PFSA:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	-3.48%
Technical	Upgrade to Pro to unlock	-2.28%
Technical	Upgrade to Pro to unlock	-2.19%
Technical	Upgrade to Pro to unlock	+2.18%
Technical	Upgrade to Pro to unlock	+1.97%
Technical	Upgrade to Pro to unlock	-1.56%
Technical	Upgrade to Pro to unlock	+1.52%
Technical	Upgrade to Pro to unlock	-1.43%
Technical	Upgrade to Pro to unlock	+1.30%
Technical	Upgrade to Pro to unlock	-1.28%
Technical	Upgrade to Pro to unlock	+1.18%
Technical	Upgrade to Pro to unlock	-1.18%
Technical	Upgrade to Pro to unlock	+1.17%
Technical	Upgrade to Pro to unlock	+1.05%
Technical	Upgrade to Pro to unlock	-1.03%

Rest of Alpha Signals: -4.84%

PFSA probability advantage of beating the market (only technical, 3M)Total:-8.91%
PFSA Technical Score

Significant changes Vs previous day

PFSA Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$0.09
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

PFSA Proven Sell Signal & Price Forecast

This is the price chart for PFSA from January 2, 2026 until today. The chart indicates, in red, the 113 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

PFSA Average Past Performance & Loss Rate

Three months after its 225 Sell signals since July 2026, PFSA had an average performance of xxxxxxx and a xxxxxxx Loss rate (negative performance).

225 Past PFSA Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				0.00%
Average Alpha				0.00%
Loss Rate (% Negative Perf.)				100.00%
% Negative Alpha				100.00%

PFSA Frequently Asked Questions

Will Profusa stock go up?
According to Danelfin AI, Profusa has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (36.77%) is -14.05% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Profusa stock?
Is it a good time to buy, sell, or hold Profusa stock right now?
Is Profusa undervalued right now?
What was the price range of Profusa stock over the past 12 months?
What is going on with Profusa stock in the last 3 months?
Does Profusa offer dividend payments?
What is the current market capitalization of Profusa?

Profusa Inc Company Profile

Profusa Inc (PFSA) develops miniature, injectable biosensors for continuous, real-time monitoring of body chemistry. The company provides advanced medical devices and data platforms for healthcare professionals and researchers. These solutions offer persistent physiological data for various medical and health management applications.

The core technology involves hydrogel-based biosensors designed for subcutaneous implantation. These sensors are engineered to be biocompatible, allowing them to function for extended periods within the body. They measure various biomarkers directly within the interstitial fluid, offering a less invasive alternative to traditional blood draws. This approach enables long-term, continuous data collection without repeated invasive procedures. The system includes a small, wearable reader that wirelessly communicates with the implanted sensor. This reader then transmits the collected physiological data to a secure digital platform for analysis and interpretation.

Profusa's platforms deliver actionable insights for health management, disease detection, and personalized medicine. The technology supports continuous monitoring in diverse clinical settings and for chronic disease management. For example, the Lumee Oxygen Platform continuously monitors tissue oxygen levels. This application assists in managing conditions like chronic wounds or peripheral artery disease. It also supports other conditions requiring ongoing physiological assessment. The collected data helps clinicians make timely and informed treatment decisions. Beyond oxygen, the biosensors can track other analytes, including glucose, lactate, or other metabolic indicators. This provides a comprehensive view of a patient's metabolic state over time.

The company serves healthcare enterprises, research institutions, and government agencies. These customers focus on advanced medical diagnostics and continuous physiological monitoring. Profusa distributes its products through direct sales channels and strategic partnerships with medical device companies. Profusa generates revenue from product sales, including biosensors and associated reading devices, and from service fees; recurring elements stem from sensor replacements and data platform subscriptions, with go-to-market through direct and channel distribution to customers globally.

Sector:Health Care
Country:United States
Industry:
Address:207 West 25Th St, 9Th Floor, New York City
Employees:0
Website:profusa.com

Pros

High switching costs for integrated monitoring systems

Proprietary biosensor technology and intellectual property

Growing demand for continuous physiological data

Scalable data analytics platform for health insights

Regulatory barriers to entry for implantable medical devices

Cons

Substantial capital intensity for device development

Lengthy and uncertain regulatory approval pathways

Challenges in securing favorable reimbursement coverage

Patient adoption barriers due to device invasiveness

Competition from non-invasive wearable monitoring solutions

Company	AI Score	Compare
PROFProfound Medical Corp
INBSIntelligent Bio Solutions Inc
PHRPhreesia Inc
LIVNLivaNova PLC

Company	AI Score	Compare
PROFProfound Medical Corp
INBSIntelligent Bio Solutions Inc
PHRPhreesia Inc
LIVNLivaNova PLC

PFSA Stock AI Analysis High Risk

Profusa Inc

PFSA Stock AI Analysis

Profusa Inc

PFSA AI-Powered Stock Analysis

AI Score Explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

PFSA probability advantage of beating the market (only technical, 3M): -8.91%

PFSA Short Trading Parameters

PFSA Proven Sell Signal & Price Forecast

PFSA Average Past Performance & Loss Rate

PFSA Frequently Asked Questions

Will Profusa stock go up?

What is the target price for Profusa stock?

Is it a good time to buy, sell, or hold Profusa stock right now?

Is Profusa undervalued right now?

What was the price range of Profusa stock over the past 12 months?

What is going on with Profusa stock in the last 3 months?

Does Profusa offer dividend payments?

What is the current market capitalization of Profusa?

Profusa Inc Company Profile

Pros

Cons

Pros

Cons

PFSA Company Profile Summary

PFSA Related Investment Themes

PFSA Related Stocks

PFSA Top 10 Industry Stocks

Health Care Equipment & Supplies

PFSA Top 10 Sector Stocks

Health Care

PFSA Stock AI Analysis High Risk

Profusa Inc

NASDAQ NMS - GLOBAL MARKET

Will Profusa stock go up?

What is the target price for Profusa stock?

Is it a good time to buy, sell, or hold Profusa stock right now?

Is Profusa undervalued right now?

What was the price range of Profusa stock over the past 12 months?

What is going on with Profusa stock in the last 3 months?

Does Profusa offer dividend payments?

What is the current market capitalization of Profusa?

NASDAQ NMS - GLOBAL MARKET

PFSA Proven Sell Signal & Price Forecast

Pros

Cons

AI Score Explanation